A recent intervention by Maharashtra Food and Drug Administration (FDA) Commissioner Tukaram Mundhe has brought renewed attention to the pricing of medical consumables used in hospitals.
Mundhe has written to the Department of Pharmaceuticals and the National Pharmaceutical Pricing Authority (NPPA), seeking a review of the large differences between the procurement prices and printed maximum retail prices (MRPs) of several commonly used hospital consumables.
The issue has now reached the Centre. Union Health and Chemicals and Fertilisers Minister J. P. Nadda has directed the Department of Pharmaceuticals and NPPA to hold discussions with hospitals and other stakeholders regarding the pricing and mark-ups of hospital consumables. The Centre has also sought an NPPA report on the issue.
The ₹11.05 IV set that brought the issue into focus
One of the examples cited by Mundhe is an intravenous infusion set.
According to the Maharashtra FDA survey, an IV infusion set was procured at a trade price of ₹11.05, while the printed MRP on the product was ₹325.
The difference between the two prices is substantial. Based on the trade price, the MRP is about 29 times higher, equivalent to a markup of approximately 2,841 per cent.
Mundhe highlighted this example to raise questions about how prices of essential medical consumables are determined and how much information patients have about the actual cost of the products used during their treatment.
Other medical consumables also showed large price differences
The Maharashtra FDA survey found similar gaps in other commonly used products.
A syringe procured at ₹6.75 was reported to carry an MRP of ₹57.20.
A catheter purchased at ₹29.41 was reported to have an MRP of ₹310.
The survey also examined products such as nebulisers, oxygen masks, IV sets and other consumables used during inpatient treatment.
These figures compare the reported procurement or trade price with the printed MRP. They should not, by themselves, be interpreted as the hospital’s profit on each item. The final economics can involve manufacturers, distributors, suppliers, hospitals and the costs associated with storage and providing healthcare services.
Why the issue matters to patients
Medical consumables are different from ordinary consumer products.
A person buying an everyday product can compare prices between shops, select another brand or postpone the purchase. A patient undergoing hospital treatment generally does not have the same freedom.
Items such as IV sets, syringes, catheters, oxygen masks and other consumables may be required as part of medical treatment. Patients may therefore have little opportunity to compare prices or choose alternatives at the time they are being used.
Mundhe has argued that this creates an information gap because the person ultimately paying the bill may not know the procurement price of the product or how its MRP was determined.
What did the Maharashtra FDA survey find?
The survey was conducted in July across hospitals in the Mumbai Metropolitan Region, Pune and Chhatrapati Sambhajinagar.
The Maharashtra FDA subsequently submitted its findings to the NPPA in the first week of August. The department said the exercise followed complaints concerning high charges for consumables and medical devices used for inpatient treatment.
The FDA has also clarified an important point: it does not have jurisdiction to regulate hospital bills or the charges hospitals impose for admission and procedures. Its role in this matter was to bring the pricing issue to the attention of the NPPA, which has authority under the relevant pricing framework.
Why is there a regulatory question?
India already has a system of price regulation for certain medicines and specified medical devices.
Under the Drugs (Prices Control) Order, 2013, scheduled medicines are subject to statutory price controls. However, many medical consumables and devices used in hospitals are not covered by the same direct ceiling-price mechanism.
This has created a policy question about whether frequently used and essential hospital consumables should have greater price monitoring or defined limits on the difference between procurement prices and declared MRPs.
Mundhe has recommended that the government examine the issue and consider clear guidelines regarding permissible differences between trade procurement prices and declared MRPs.
What has Tukaram Mundhe asked the Centre to consider?
The Maharashtra FDA’s intervention is not limited to one particular IV set or syringe.
The broader proposal is to examine the pricing mechanism for frequently used medical devices and consumables and consider measures such as greater price monitoring and rationalisation of trade margins.
The objective is to establish a framework in which the prices of essential medical consumables are more transparent and the interests of patients, manufacturers, distributors, hospitals and regulators are considered.
Importantly, there is currently no confirmed decision to impose a uniform price cap on all hospital consumables. The government is examining the matter and consulting stakeholders before deciding on any policy intervention.
The Centre begins consultations
The issue has moved beyond Maharashtra.
On September 19, Union Minister J. P. Nadda directed the Department of Pharmaceuticals and NPPA to engage with stakeholders from the medical sector and hospitals regarding the reported high mark-ups on hospital consumables.
The Department of Pharmaceuticals has also begun discussions with private hospitals to understand their procurement practices, billing mechanisms and the costs associated with inpatient care. Reports indicate that representatives of several hospital groups participated in these discussions.
This consultation is significant because the difference between procurement price and MRP cannot automatically be treated as the hospital’s profit.
Hospitals’ response
Hospital representatives have argued that comparing procurement prices with printed MRPs does not necessarily establish the actual profit earned by a hospital.
They have pointed out that hospitals incur costs related to nursing, infection control, storage, inventory management, wastage, administration and clinical infrastructure. Hospitals may also operate under pre-determined package rates, particularly for insured patients.
The Association of Healthcare Providers (India), for example, has argued that the MRP does not by itself represent the hospital’s complete economics of providing treatment.
This distinction is important when interpreting the Maharashtra FDA figures.
The reported price differences are a reason for regulatory examination, but they are not by themselves proof that the entire difference between procurement price and MRP becomes a hospital’s profit.
What could change if the government introduces new rules?
If the Centre eventually decides to introduce a new framework, several approaches could be considered.
These could include defining permissible trade margins for selected essential consumables, bringing additional medical devices under structured price monitoring, improving disclosure of procurement and billing information, or establishing product-specific pricing mechanisms.
Any such framework would need to consider the entire supply chain, including manufacturing costs, distribution, hospital operating costs and patient affordability.
The Centre has not yet announced a final policy. The current stage is one of examination and consultation.
Why transparency may be as important as price control
The debate is not simply about whether an IV set should cost ₹11, ₹100 or ₹325.
A larger question is whether patients should have sufficient information to understand what they are being charged for essential medical products.
Greater transparency could allow patients and insurers to understand the basis of consumable charges more clearly, while also allowing regulators to identify unusually large price differences.
At the same time, any regulatory system would need to distinguish between the printed MRP, the hospital’s actual procurement price, the price charged to the patient and the hospital’s total cost of providing treatment.
What should patients look for in a hospital bill?
Patients and their families can ask for an itemised hospital bill showing the medicines, medical devices and consumables used during treatment.
They can also check the product name, quantity, MRP and amount charged for individual items and retain copies of invoices and discharge documents.
For planned procedures, patients may also ask the hospital in advance whether consumables are included in the treatment package or billed separately.
However, patients should not assume that the difference between an item’s procurement price and MRP represents the hospital’s profit without knowing the complete billing and cost structure.
A wider debate over healthcare affordability
The controversy surrounding hospital consumables comes at a time when healthcare affordability and transparency remain important public-policy issues.
Medical treatment can involve not only doctors’ fees and medicines but also a large number of devices and consumables used during diagnosis, surgery and inpatient care.
The Maharashtra FDA’s findings have therefore opened a broader discussion about how these products should be priced and monitored.
The involvement of the NPPA and the Department of Pharmaceuticals means that the issue is now being examined at the national level.
What happens next?
The immediate next step is consultation.
The NPPA is expected to examine the information submitted by Maharashtra and the Department of Pharmaceuticals is consulting hospitals and other stakeholders.
The government will then have to decide whether the existing framework is sufficient or whether additional measures are required for commonly used medical consumables.
For patients, the central question is straightforward: when an essential medical product is used during treatment, how can its price be made reasonable, transparent and understandable?
The ₹11.05 IV set carrying an MRP of ₹325 has brought that question into sharp focus. The eventual policy response will determine whether this episode results in changes to the way medical consumables are priced and disclosed across India’s healthcare system.
